Genetic signatures obtained from intestinal mucosa have an 89% accuracy for predicting which patients with inflammatory bowel disease will not respond to treatment with three classes of therapeutic agents, new research shows.
The tool, which is not yet commercially available, “could reshape our approach to clinical trials and treatment,” according to the investigators, who presented the findings at the 2019 meeting of the European Crohn’s and Colitis Organisation (oral